- 专利标题： CROSSLINKED ARTIFICIAL NUCLEIC ACID ALNA
-
申请号： US17292963申请日： 2019-11-11
-
公开(公告)号： US20220002336A1公开(公告)日： 2022-01-06
- 发明人: Hiroaki SAWAMOTO , Shinji KUMAGAI , Hiroyuki FURUKAWA , Tomo ARAKI , Masayuki UTSUGI , Satoshi OBIKA
- 申请人： MITSUBISHI TANABE PHARMA CORPORATION , OSAKA UNIVERSITY
- 申请人地址： JP Osaka-shi, Osaka; JP Suita-shi, Osaka
- 专利权人： MITSUBISHI TANABE PHARMA CORPORATION,OSAKA UNIVERSITY
- 当前专利权人： MITSUBISHI TANABE PHARMA CORPORATION,OSAKA UNIVERSITY
- 当前专利权人地址： JP Osaka-shi, Osaka; JP Suita-shi, Osaka
- 优先权： JP2018-212424 20181112
- 国际申请： PCT/JP2019/044182 WO 20191111
- 主分类号： C07H19/20
- IPC分类号： C07H19/20 ; C07H19/10 ; C07H21/04
摘要：
The present invention provides a novel bridged artificial nucleic acid and an oligomer containing the same as a monomer. The present invention provides specifically a compound represented by general formula (I) (wherein each symbol is the same as defined in the specification) or salts thereof; as well as an oligonucleotide compound represented by general formula (I′) (wherein each symbol is the same as defined in the specification) or salts thereof.
信息查询
IPC分类:
